Liver CancerNCT07010315
Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
An observational study of Liver Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To develop and test liver cancer prevention educational material. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Liver Cancer
- What is being tested?
- Cognitive Testing and Usability Testing
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 1 May 2025to 30 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants at HOPE Clinic
Who may be able to join
- At least 18 years old
- Participants at the HOPE Clinic
- Able to speak and read either English or Spanish
- For usability testing: Able to use and navigate websites on own smart phone or study computer
Who cannot join
- Has been diagnosed with liver cancer
- Cannot provide consent or otherwise participate in research activities (e.g. vision or hearing impairment)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Jessica Hwang, MD, MPH, 346-720-7352, jphwang@mdanderson.org
Jessica Hwang, MD, MPH
About this study
To develop and test liver cancer prevention educational material.
Read the detailed description
Primary Objectives:
- To ensure the text for the site is understood by participants, participant comprehension will be measured qualitatively through cognitive testing. Adjustments will be made to the content, messages, and layout iteratively until interviewer notes show no large discrepancies between participant understanding and the meaning of the text.
- To ensure the site is easy to use, usability will be measured qualitatively through usability testing. Adjustments will be made to the functionality of the patient-facing portions of the web-based tool iteratively until interviewer notes indicate that participants are able to input their risk factors and download the personal summary on their own.
Secondary Objectives:
- To describe whether the site is acceptable to users, acceptability will be measured (as part of usability testing) with the Ottawa Acceptability Measures.
- To describe participants' knowledge of liver cancer risk factors, knowledge will be measured (as part of usability testing) with Knowledge Questions developed for this study.
- Conditions
- Liver Cancer
- Being tested
- Cognitive Testing, Usability Testing
- Keywords
- Liver cancer, Liver disease, Fibrosis, Cirrhosis
- Medical subject headings
- Liver Neoplasms, Liver Diseases, Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive TestingBehavioural
Given by Survey and one-on one interviews
Usability TestingBehavioural
Given by surveys and one-on-one interview.
| Study group | Role | What they receive |
|---|---|---|
| Cognitive Interviews (English and Spanish) | Participants that agree to this part of the study will be asked to view patient education materials about liver cancer, complete a demographic survey, and do an interview one-on-one either online via Zoom, over the phone, or in person at HOPE Clinic. Receives: Behavioral: Cognitive Testing | |
| Usability Testing (English and Spanish) | Participants will be asked to complete a pre-survey, navigate a liver cancer education website, provide their feedback and impressions, and complete a post- survey. Receives: Behavioral: Usability Testing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive Testing
Participant comprehension will be measured qualitatively through cognitive testing. In cognitive testing interviews, participants are asked to "think aloud" as they review and react to new information. Participants will be presented with the storyboard (mock-up) versions of the content and asked to describe in their own words what the information means to them. Cognitive interviews may include questions about content such as length, clarity of the language, and helpfulness of the educational material. A trained research team member will ask probing questions throughout interviews as needed. Based on patient feedback, modifications will be made iteratively to the content to ensure the content is understood and interpreted as intended. There is no post-survey for cognitive testing.
Measured: Up to 1.5 hours
Usability Testing
Usability will be measured qualitatively using a Usability Interview Guide. Usability will also be measured using the System Usability Scale. Acceptability will be measured with the Ottawa Acceptability Measures. Knowledge will be measured pre- and post- session using knowledge questions developed by the investigators and refined during cognitive testing.
Measured: Up to 1.5 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2025
- Study start1 May 2025
- Primary completion30 Apr 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Cancer Prevention Research Institute of Texas
- Responsible party
- Sponsor
- Investigators
- Jessica Hwang, MD, MPH, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07010315
- Sponsor's protocol ID
- 2025-0299
- Other IDs
- NCI-2025-03535
- Status last verified
- Mar 2026
- First submitted
- 9 May 2025
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
- ClinicalTrials.gov ID
- NCT07010315
- Acronym / sponsor ID
- 2025-0299
- Conditions
- Liver Cancer
- Keywords
- Liver cancer, Liver disease, Fibrosis, Cirrhosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- Cancer Prevention Research Institute of Texas
- Study start
- 1 May 2025 (actual)
- Primary completion
- 30 Apr 2027 (estimated)
- Study completion
- 30 Apr 2027 (estimated)
- First posted
- 8 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To develop and test liver cancer prevention educational material.
Detailed description
Primary Objectives:
- To ensure the text for the site is understood by participants, participant comprehension will be measured qualitatively through cognitive testing. Adjustments will be made to the content, messages, and layout iteratively until interviewer notes show no large discrepancies between participant understanding and the meaning of the text.
- To ensure the site is easy to use, usability will be measured qualitatively through usability testing. Adjustments will be made to the functionality of the patient-facing portions of the web-based tool iteratively until interviewer notes indicate that participants are able to input their risk factors and download the personal summary on their own.
Secondary Objectives:
- To describe whether the site is acceptable to users, acceptability will be measured (as part of usability testing) with the Ottawa Acceptability Measures.
- To describe participants' knowledge of liver cancer risk factors, knowledge will be measured (as part of usability testing) with Knowledge Questions developed for this study.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cognitive Interviews (English and Spanish) | – | Behavioral: Cognitive TestingParticipants that agree to this part of the study will be asked to view patient education materials about liver cancer, complete a demographic survey, and do an interview one-on-one either online via Zoom, over the phone, or in person at HOPE Clinic. |
| Usability Testing (English and Spanish) | – | Behavioral: Usability TestingParticipants will be asked to complete a pre-survey, navigate a liver cancer education website, provide their feedback and impressions, and complete a post- survey. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants at HOPE Clinic
Key inclusion criteria (4 listed)
- At least 18 years old
- Participants at the HOPE Clinic
- Able to speak and read either English or Spanish
- For usability testing: Able to use and navigate websites on own smart phone or study computer
Key exclusion criteria (2 listed)
- Has been diagnosed with liver cancer
- Cannot provide consent or otherwise participate in research activities (e.g. vision or hearing impairment)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive TestingGiven by Survey and one-on one interviews | Behavioural | Cognitive Interviews (English and Spanish) |
| Usability TestingGiven by surveys and one-on-one interview. | Behavioural | Usability Testing (English and Spanish) |
Primary outcome
Cognitive Testing
Time frame: Up to 1.5 hours
Participant comprehension will be measured qualitatively through cognitive testing. In cognitive testing interviews, participants are asked to "think aloud" as they review and react to new information. Participants will be presented with the storyboard (mock-up) versions of the content and asked to describe in their own words what the information means to them. Cognitive interviews may include questions about content such as length, clarity of the language, and helpfulness of the educational material. A trained research team member will ask probing questions throughout interviews as needed. Based on patient feedback, modifications will be made iteratively to the content to ensure the content is understood and interpreted as intended. There is no post-survey for cognitive testing.
Usability Testing
Time frame: Up to 1.5 hours
Usability will be measured qualitatively using a Usability Interview Guide. Usability will also be measured using the System Usability Scale. Acceptability will be measured with the Ottawa Acceptability Measures. Knowledge will be measured pre- and post- session using knowledge questions developed by the investigators and refined during cognitive testing.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
- MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Liver Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Not yet recruitingPhase 3
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Not yet recruiting
Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-Resectable
RecruitingPhase 2
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma, HCC
Active, not recruitingPhase 2
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jessica Hwang, MD, MPH principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jessica Hwang, MD, MPH ((346) 720-7352, jphwang@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive Testing (time frame: Up to 1.5 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.